Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Telmisartan: they're closely matched on evidence (4.5 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Empagliflozin and Telmisartan are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Empagliflozin and Telmisartan have evidence — compare verdict strength side-by-side.
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
Approved antihypertensive dosing is 20–80 mg once daily; the metabolic/PPARγ effects are most evident at the higher 80 mg (and study) doses, under a clinician. Not an approved metabolic or longevity regimen; blood pressure, kidney function, and potassium should be monitored.
morning
Oral tablet (telmisartan)
Months to years
Months to years
Weeks to months
Throughout use
Months to years
Weeks to months
Years
Throughout use
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Telmisartan, ramipril, or both in patients at high risk for vascular events.
The New England journal of medicine (2008) · Rct · n=25620
ONTARGET randomized 25,620 high-vascular-risk patients to ramipril, telmisartan, or both
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet (London, England) (2008) · Rct · n=25620
Prespecified ONTARGET renal analysis of the same 25,620 patients
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Lancet (London, England) (2008) · Rct · n=5926
TRANSCEND randomized 5,926 ACE-inhibitor-intolerant high-risk patients to telmisartan or placebo
Both Empagliflozin and Telmisartan are closely matched — the best choice depends on your specific health goals.
For support heart health, Empagliflozin has a higher relevance score (72 vs 66).
No known interactions between Empagliflozin and Telmisartan have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.